Wieduwilt, MJ, Metheny, L, Zhang, MJ, Wang, HL, Estrada-Merly, N, Marks, DI, Al-Homsi, AS, Muffly, L, Chao, N, Rizzieri, D, Gale, RP, Gadalla, SM, Cairo, M, Mussetti, A, Gore, S, Bhatt, VR, Patel, SS, Michelis, FV, Inamoto, Y, Badawy, SM, Copelan, E, Palmisiano, N, Kharfan-Dabaja, MA, Lazarus, HM, Ganguly, S, Bredeson, C, Perez, MAD, Cassaday, R, Savani, BN, Ballen, K, Martino, R, Wirk, B, Bacher, U, Aljurf, M, Bashey, A, Murthy, HS, Yared, JA, Aldoss, I, Farhadfar, N, Liu, HT, Abdel-Azim, H, Waller, EK, Solh, M, Seftel, MD, van der Poel, M, Grunwald, MR, Liesveld, JL, Kamble, RT, McGuirk, J, Munker, R, Cahn, JY, Lee, JW, Freytes, CO, Krem, MM, Winestone, LE, Gergis, U, Nathan, S, Olsson, RF, Verdonck, LF, Sharma, A, Ringden, O, Friend, BD, Cerny, J, Choe, H, Chhabra, S, Nishihori, T, Seo, S, George, B, Baxter-Lowe, LA, Hildebrandt, GC, de Lima, M, Litzow, M, Kebriaei, P, Hourigan, CS, Abid, MB, Weisdorf, DJ, Saber, W. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances. 2022; 6(1)DOI:10.1182/bloodadvances.2021004916. PMID:34547770. IF:7.500(Q1/2D).

Mikulska, M, Knelange, N, Nicolini, LA, Tridello, G, Santarone, S, Di Bartolomeo, P, de la Camara, R, Cuellar, C, Velardi, A, Perruccio, K, Ljungman, P, Zaucha, J, Piekarska, A, Basak, G, Karakulska-Prystupiuk, E, Angelucci, E, Ciceri, F, Lupo-Stanghellini, MT, Fouillard, L, Garcia-Cadenas, I, Menconi, M, Blau, IW, Nassi, L, Cesaro, S, Styczynski, J. Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMT. JOURNAL OF INFECTION. 2022; 84(1)DOI:10.1016/j.jinf.2021.10.024. PMID:34757138. IF:28.200(Q1/1D).

Serna, N, Falgas, A, Garcia-Leon, A, Unzueta, U, Nunez, Y, Sanchez-Chardi, A, Martinez-Torro, C, Mangues, R, Vazquez, E, Casanova, I, Villaverde, A. Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials. Pharmaceutics. 2022; 14(1)DOI:10.3390/pharmaceutics14010192. PMID:35057088. IF:5.400(Q1/2D).

Wierda, WG, Allan, JN, Siddiqi, T, Kipps, TJ, Opat, S, Tedeschi, A, Badoux, XC, Kuss, BJ, Jackson, S, Moreno, C, Jacobs, R, Pagel, JM, Flinn, I, Pak, Y, Zhou, C, Szafer-Glusman, E, Ninomoto, J, Dean, JP, James, DF, Ghia, P, Tam, CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(34)DOI:10.1200/JCO.21.00807. PMID:34618601. IF:50.739(Q1/1D).

Dickinson, M, Briones, J, Herrera, AF, Gonzalez-Barca, E, Ghosh, N, Cordoba, R, Rutherford, SC, Bournazou, E, Labriola-Tompkins, E, Franjkovic, I, Chesne, E, Brouwer-Visser, J, Lechner, K, Brennan, B, Nuesch, E, DeMario, M, Ruttinger, D, Kornacker, M, Hutchings, M. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. Blood Advances. 2021; 5(22)DOI:10.1182/bloodadvances.2021004619. PMID:34581757. IF:7.642(Q1/3D).

Caballero A.C., Escribà-Garcia L., Pujol-Fernández P., Escudero-López E., Ujaldón-Miró C., Montserrat-Torres R., Sierra J., Alvarez-Fernández C., Briones J.. High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion. CANCER GENE THERAPY. 2023; 30(1)DOI:10.1038/s41417-022-00518-6. PMID:36031661. IF:4.800(Q1/2D).

Del Principe, MI, Seidel, D, Criscuolo, M, Dargenio, M, Racil, Z, Piedimonte, M, Marchesi, F, Nadali, G, Koehler, P, Fracchiolla, N, Cattaneo, C, Klimko, N, Spolzino, A, Karapinar, DY, Demiraslan, H, Duarte, RF, Demeter, J, Stanzani, M, Melillo, LMA, Basilico, CM, Cesaro, S, Paterno, G, Califano, C, Delia, M, Buzzatti, E, Busca, A, Cornely, OA, Pagano, L, Alakel, N, Arsenijevi'c, VA, Camus, V, Falces-Romero, I, Itzhak, L, Kouba, M, Martino, R, Sedlacek, P, Weinbergerova, B. Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope. MYCOSES. 2023; 66(1)DOI:10.1111/myc.13524. PMID:36064299. IF:4.100(Q1/2D).

Diaz-Santa, J, Rodriguez-Romanos, R, Coll, R, Osca, G, Pratcorona, M, Gonzalez-Bartulos, M, Garrido, A, Angona, A, Talarn, C, Tormo, M, Arnan, M, Vives, S, Salamero, O, Tuset, E, Lloveras, N, Diez, I, Zamora, L, Bargay, J, Sampol, A, Cruz, D, Vila, J, Sitges, M, Garcia, A, Vall-Llovera, F, Esteve, J, Sierra, J, Gallardo, D. 5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics. EUROPEAN JOURNAL OF HAEMATOLOGY. 2022; 109(6)DOI:10.1111/ejh.13862. PMID:36063368. IF:3.100(Q3/6D).

Baptista, MJ, Tapia, G, Munoz-Marmol, AM, Muncunill, J, Garcia, O, Montoto, S, Gribben, JG, Calaminici, M, Martinez, A, Veloza, L, Martinez-Trillos, A, Aldamiz, T, Menarguez, J, Terol, MJ, Ferrandez, A, Alcoceba, M, Briones, J, Gonzalez-Barca, E, Climent, F, Muntanola, A, Moraleda, JM, Provencio, M, Abrisqueta, P, Abella, E, Colomo, L, Garcia-Ballesteros, C, Garcia-Caro, M, Sancho, JM, Ribera, JM, Mate, JL, Navarro, JT. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications. HISTOPATHOLOGY. 2022; 81(6)DOI:10.1111/his.14798. PMID:36109172. IF:6.400(Q1/2D).

Albiol, N, Barata, A, Aso, O, Gomez-Perez, L, Triquell, M, Roch, N, Lazaro, E, Esquirol, A, Gonzalez, I, Lopez-Contreras, J, Sierra, J, Martino, R, Garcia-Cadenas, I. mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients. SUPPORTIVE CARE IN CANCER. 2022; 30(12)DOI:10.1007/s00520-022-07376-w. PMID:36169731. IF:3.100(Q1/3D).

Merino, M, Ivanova, Y, Maravilla-Herrera, P, Barragan, B, Sierra, J, Penuelas-Saiz, A, Hidalgo-Vega, A. Optimising the management of patients with multiple myeloma in Spain: A measurement of the social return on investment. EUROPEAN JOURNAL OF CANCER CARE. 2022; 31(6)DOI:10.1111/ecc.13706. PMID:36177961. IF:2.100(Q2/4D).

Nagler, A, Labopin, M, Cornelissen, JJ, Forcade, E, Chevallier, P, Fegueux, N, Sierra, J, Desmier, D, Labussiere-Wallet, H, Byrne, JL, Loschi, M, Blaise, D, Baron, F, Ruggeri, A, Mohty, M. Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). BONE MARROW TRANSPLANTATION. 2022; 57(10)DOI:10.1038/s41409-022-01742-2. PMID:35773347. IF:4.800(Q1/2D).

Pinana, JL, Rodriguez-Belenguer, P, Caballero, D, Martino, R, Lopez-Corral, L, Terol, MJ, Vazquez, L, Calabuig, M, Sanz-Linares, G, Marin-Jimenez, F, Alonso, C, Montoro, J, Ferrer, E, Facal, A, Pascual, MJ, Rodriguez-Fernandez, A, Olave, MT, Cascales-Hernandez, A, Gago, B, Hernandez-Rivas, JA, Villalon, L, Corona, M, Roldan-Perez, A, Ribes-Amoros, J, Gonzalez-Santillana, C, Garcia-Sanz, R, Navarro, D, Serrano-Lopez, AJ, Cedillo, A, Soria-Olivas, E, Sureda, A, Solano, C. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. ANNALS OF HEMATOLOGY. 2022; 101(9)DOI:10.1007/s00277-022-04906-8. PMID:35780254. IF:3.500(Q2/5D).

Guijarro, F, Bataller, A, Diaz-Beya, M, Garrido, A, Coll-Ferra, C, Vives, S, Salamero, O, Valcarcel, D, Tormo, M, Arnan, M, Sampol, A, Castano-Diez, S, Martinez, C, Suarez-Lledo, M, Fernandez-Aviles, F, Hernandez-Boluda, JC, Ribera, JM, Rovira, M, Brunet, S, Sierra, J, Esteve, J. Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. BONE MARROW TRANSPLANTATION. 2022; 57(8)DOI:10.1038/s41409-022-01703-9. PMID:35643942. IF:4.800(Q1/2D).

Moreno, DF, Clapes, V, Soler, JA, Gonzalez-Montes, Y, Gironella, M, Motllo, C, Granell, M, Abella, E, Garcia-Pintos, M, Garcia-Guinon, A, Cabezudo, E, Blade, J, Rosinol, L. Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas. Clinical Lymphoma Myeloma & Leukemia. 2022; 22(8)DOI:10.1016/j.clml.2022.04.014. PMID:35610120. IF:2.700(Q3/7D).

Ramos-Campoy, S, Puiggros, A, Kamaso, J, Bea, S, Bougeon, S, Larrayoz, MJ, Costa, D, Parker, H, Rigolin, GM, Blanco, ML, Collado, R, Ancin, I, Salgado, R, Moro-Garcia, MA, Baumann, T, Gimeno, E, Moreno, C, Salido, M, Calvo, X, Calasanz, MJ, Cuneo, A, Nguyen-Khac, F, Oscier, D, Haferlach, C, Strefford, JC, Schoumans, J, Espinet, B. TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype. Cancers. 2022; 14(15)DOI:10.3390/cancers14153715. PMID:35954380. IF:5.200(Q2/3D).

Caballero, AC, Escriba-Garcia, L, Alvarez-Fernandez, C, Briones, J. CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure. Frontiers in Immunology. 2022; 13DOI:10.3389/fimmu.2022.904497. PMID:35874685. IF:7.300(Q1/3D).

Perl, AE, Larson, RA, Podoltsev, NA, Strickland, S, Wang, ES, Atallah, E, Schiller, GJ, Martinelli, G, Neubauer, A, Sierra, J, Montesinos, P, Recher, C, Yoon, SS, Hosono, N, Onozawa, M, Chiba, S, Kim, HJ, Hasabou, N, Lu, QY, Tiu, R, Levis, MJ. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. BLOOD. 2022; 139(23)DOI:10.1182/blood.2021011583. PMID:35081255. IF:20.300(Q1/1D).

Tam, CS, Allan, JN, Siddiqi, T, Kipps, TJ, Jacobs, R, Opat, S, Barr, PM, Tedeschi, A, Trentin, L, Bannerji, R, Jackson, S, Kuss, BJ, Moreno, C, Szafer-Glusman, E, Russell, K, Zhou, C, Ninomoto, J, Dean, JP, Wierda, WG, Ghia, P. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. BLOOD. 2022; 139(22)DOI:10.1182/blood.2021014488. PMID:35196370. IF:20.300(Q1/1D).

Dreyling, M, Andre, M, Gokbuget, N, Tilly, H, Jerkeman, M, Gribben, J, Ferreri, A, Morel, P, Stilgenbauer, S, Fox, C, Ribera, JM, Zweegman, S, Aurer, I, Bodor, C, Burkhardt, B, Buske, C, Caballero, MD, Campo, E, Chapuy, B, Davies, A, de Leval, L, Doorduijn, J, Federico, M, Gaulard, P, Gay, F, Ghia, P, Gronbaek, K, Goldschmidt, H, Kersten, MJ, Kiesewetter, B, Landman-Parker, J, Le Gouill, S, Lenz, G, Leppa, S, Lopez-Guillermo, A, Macintyre, E, Mantega, MVM, Moreau, P, Moreno, C, Nadel, B, Okosun, J, Owen, R, Pospisilova, S, Pott, C, Robak, T, Spina, M, Stamatopoulos, K, Stary, J, Tarte, K, Tedeschi, A, Thieblemont, C, Trappe, RU, Trumper, LH, Salles, G. The EHA Research Roadmap: Malignant Lymphoid Diseases. Hemasphere. 2022; 6(6)DOI:10.1097/HS9.0000000000000726. PMID:35620592. IF:6.600(Q1/3D).